In Q2 2026, OrbiMed Advisors held 111 positions worth $5.1B. They initiated 15 new positions and exited 115. Their largest holding was EWTX ($630.5M). Portfolio value grew +19.9% versus the prior quarter.
Frequently asked questions
What stocks did OrbiMed Advisors own in Q2 2026?
OrbiMed Advisors held 111 biotech stocks in their 13F portfolio in Q2 2026. Their top positions include EWTX, ELVN, LLY, MBX, SVA. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was OrbiMed Advisors's portfolio worth in Q2 2026?
OrbiMed Advisors's tracked biotech portfolio was worth $5.1B across 111 positions, with total assets under management of approximately $19B. Portfolio values are based on 13F filings with the SEC.
What did OrbiMed Advisors buy in Q2 2026?
OrbiMed Advisors initiated 15 new positions in Q2 2026, including ODTX, AURA, MNPR, TSHA, SPRB and 10 more. They also increased 44 existing positions.
What did OrbiMed Advisors sell in Q2 2026?
OrbiMed Advisors fully exited 115 positions in Q2 2026, including AGIO, AVTX, AKRO, MNMD, TIL and 110 more. They also trimmed 26 existing positions.
Is OrbiMed Advisors a biotech fund?
One of the world's largest healthcare-dedicated investment firms, managing assets across public equity, private equity, royalties, and credit. OrbiMed's team of 100+ professionals includes physicians and PhDs covering all healthcare sub-sectors, with particular depth in biotech and pharma.
Want AI analysis, insider signals, and catalyst overlays for OrbiMed Advisors?
View latest OrbiMed Advisorsportfolio →